Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible

被引：8
作者：
Fogarty G.B. [1 ,2 ,6 ]
Hong A. [1 ,2 ,6 ]
Jacobsen K.D. [3 ]
Reisse C.H. [3 ]
Shivalingam B. [1 ,2 ]
Burmeister B. [5 ,6 ]
Haydu L.E. [1 ,4 ]
Paton E. [4 ]
Thompson J.F. [1 ,2 ]
机构：
[1] Melanoma Institute Australia, Sydney
[2] Sydney Medical School, University of Sydney, Sydney
[3] Oslo University Hospital HF, Norwegian Radium Hospital, Oslo
[4] Australia and New Zealand Melanoma Trials Group (ANZMTG), North Sydney
[5] Princess Alexandra Hospital, Brisbane
[6] Trans - Tasman Radiation Oncology Group (TROG), Newcastle
来源：
BMC Research Notes | / 7卷 / 1期
关键词：
Brain; Feasibility; Melanoma; Metastases; Pilot project; Radiotherapy; Randomised trial; Trial; Whole brain radiotherapy;
D O I：
10.1186/1756-0500-7-412
中图分类号：
学科分类号：
摘要：
Background: Brain metastases (BMs) are common in melanoma patients. Adjuvant whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases with neurosurgery and/or stereotactic radiosurgery is controversial. A randomised trial is needed. However, accrual to WBRT trials has been problematic. A pilot study by Australia and New Zealand Melanoma Trials Group (ANZMTG) was conducted to see if accrual was feasible. Methods. Sites canvassed for interest included those who treat melanoma patients, had a proven accrual in previous melanoma trials and who had the relevant infrastructure support. Feasibility forecasts from interested sites were sought. These were compared to the patient numbers documented in the research contracts. A target accrual of 60 patients in 2 years was set. Funding was sought for the pilot study. Basic demographics of the pilot study cohort were collected. Results: The first centre opened December 2008; the first patient was randomised in April 2009. The pilot accruing period concluded in September, 2011. In 30 months, 54 patients from 10 of a total of 17 activated sites in Australia (39, 72%) and in Norway (15, 28%) had been accrued. Feasibility forecasts predicted 133 trial eligible patients per year (including 108 Australian + 25 International patients). Site estimates generally overestimated accrual with 4 of 17 active sites estimating within 50% of target numbers. Sites with patient estimates calculated from records were more accurate than those estimated from memory. The overall recruitment target was lower in the research contracts when compared to the feasibility evaluation. Basic demographics of the pilot study revealed 62% of patients were males; 58% had a single metastasis, 28% had two and 14% had three metastases. 12-month overall survival was 50%. Conclusions: Despite only 54 patients and not the full 60 patient target being accrued in two years the Trial Management Committee and Data Safely Monitoring Committee approved the continuation of the pilot study to the main trial. On the basis of this successful pilot study, funding was achieved for the full study. 143 patients of a target of 200 have been randomised by June 2014. © 2014 Fogarty et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 12 条
[1]  
De La Monte S.M., Moore G.W., Hutchins G.M., Patterned distribution of metastases from malignant melanoma in humans, Cancer Research, 43, 7, pp. 3427-3433, (1983)
[2]  
Sampson J.H., Carter Jr. J.H., Friedman A.H., Seigler B.F., Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma, Journal of Neurosurgery, 88, 1, pp. 11-20, (1998)
[3]  
Fife K.M., Colman M.H., Stevens G.N., Firth I.C., Moon D., Shannon K.F., Harman R., Petersen-Schaefer K., Zacest A.C., Besser M., Milton G.W., McCarthy W.H., Thompson J.F., Determinants of outcome in melanoma patients with cerebral metastases, Journal of Clinical Oncology, 22, 7, pp. 1293-1300, (2004)
[4]  
Nicholas S., Mathios D., Jackson C., Lim M., Metastatic melanoma to the brain: Surgery and radiation is still the standard of care, Curr Treat Options Oncol, 14, 2, pp. 264-279, (2013)
[5]  
Windsor A.A., Koh E.S., Allen S., Gabriel G.S., Yeo A.E., Allison R., Van Der Linden Y.M., Barton M.B., Poor outcomes after whole brain radiotherapy in patients with brain metastases: Results from an international multicentre cohort study, Clin Oncol (R Coll Radiol), 25, 11, pp. 674-680, (2013)
[6]  
Thompson J.F., Hong A., Fogarty Letter G., Publication and Interpretation of clinical trial results: The need for caution, Ann Surg Oncol, 19, 6, pp. 1745-1747, (2012)
[7]  
Fogarty G., Morton R.L., Vardy J., Nowak A.K., Mandel C., Forder P.M., Hong A., Hruby G., Burmeister B., Shivalingam B., Dhillon H., Thompson J.F., Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-A randomised phase III trial, BMC Cancer, 11, (2011)
[8]  
Patchell R.A., Tibbs P.A., Regine W.F., Dempsey R.J., Mohiuddin M., Kryscio R.J., Markesbery W.R., Foon K.A., Young B., Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial, Journal of the American Medical Association, 280, 17, pp. 1485-1489, (1998)
[9]  
Aoyama H., Shirato H., Tago M., Nakagawa K., Toyoda T., Hatano K., Kenjyo M., Oya N., Hirota S., Shioura H., Kunieda E., Inomata T., Hayakawa K., Katoh N., Kobashi G., Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial, Journal of the American Medical Association, 295, 21, pp. 2483-2491, (2006)
[10]  
Kocher M., Soffietti R., Abacioglu U., Villa S., Fauchon F., Baumert B.G., Fariselli L., Tzuk-Shina T., Kortmann R.D., Carrie C., Ben Hassel M., Kouri M., Valeinis E., Van Den Berge D., Collette S., Collette L., Mueller R.P., Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebralmetastases: Results of the EORTC 22952-26001 study, J Clin Oncol, 29, pp. 134-141, (2011)
12